Talphera, Inc. (NASDAQ:TLPH) Short Interest Update

Talphera, Inc. (NASDAQ:TLPH) was the target of a significant decrease in short interest in the month of October. As of October 15th, there was short interest totalling 34,300 shares, a decrease of 18.9% from the September 30th total of 42,300 shares. Approximately 0.2% of the company’s shares are short sold. Based on an average daily trading volume, of 95,400 shares, the short-interest ratio is currently 0.4 days.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $6.00 price target on shares of Talphera in a research report on Friday, August 16th.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Talphera stock. Nantahala Capital Management LLC bought a new stake in shares of Talphera, Inc. (NASDAQ:TLPH) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,992,519 shares of the company’s stock, valued at approximately $1,773,000. Nantahala Capital Management LLC owned approximately 11.73% of Talphera as of its most recent SEC filing. 37.67% of the stock is owned by hedge funds and other institutional investors.

Talphera Stock Performance

NASDAQ:TLPH traded down $0.04 during midday trading on Tuesday, reaching $0.96. 20,254 shares of the stock traded hands, compared to its average volume of 92,300. The stock has a market capitalization of $16.31 million, a P/E ratio of -1.08 and a beta of 0.32. The company has a fifty day moving average of $0.91 and a 200 day moving average of $0.95. Talphera has a 12 month low of $0.43 and a 12 month high of $1.61.

Talphera (NASDAQ:TLPH) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.07. On average, analysts predict that Talphera will post -0.73 EPS for the current fiscal year.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.